The Use of Hylan G-F 20 After Knee Arthroscopy in an Active Patient Population With Knee Osteoarthritis
Purpose: The purpose of this study was to evaluate the efficacy of hylan G-F 20 when used to treat an active and athletic patient population with knee osteoarthritis who had undergone knee arthroscopy for mechanical symptoms. Methods: We performed a prospective evaluation of patients who underwent k...
Gespeichert in:
| Veröffentlicht in: | Arthroscopy 2008-04, Vol.24 (4), p.416-422 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 422 |
|---|---|
| container_issue | 4 |
| container_start_page | 416 |
| container_title | Arthroscopy |
| container_volume | 24 |
| creator | Zietz, Patrick M., M.D Selesnick, Harlan, M.D |
| description | Purpose: The purpose of this study was to evaluate the efficacy of hylan G-F 20 when used to treat an active and athletic patient population with knee osteoarthritis who had undergone knee arthroscopy for mechanical symptoms. Methods: We performed a prospective evaluation of patients who underwent knee arthroscopy for mechanical symptoms. All patients had Outerbridge grade III or IV changes to their articular cartilage. If patients complained of residual pain or activity limitations postoperatively that was believed to be from osteoarthritis, they were treated with a series of hylan G-F 20 consisting of 3 weekly injections. International Knee Documentation Committee (IKDC) and Western Ontario and McMaster University Osteoarthritis Index (WOMAC) scores are reported for the time immediately before arthroscopy, at the time of the first hylan G-F 20 injection (baseline), at 3 months postoperatively, and at 6 months postoperatively. In addition, activity scores were calculated from a subset of the IKDC questionnaire before arthroscopy, at baseline, and at 3 months postoperatively. Results: Fifteen patients completed 6 months’ follow-up. Baseline and 3- and 6-month IKDC and WOMAC scores were significantly improved compared with before arthroscopy. There was no significant difference in 3- and 6-month scores compared with baseline. The activity scores at baseline and at 3 months showed significant improvement compared with before arthroscopy. The activity scores also showed significant improvement at 3 months compared with baseline. Conclusions: Hylan G-F 20 injections allow for improved activity levels at 3 months’ follow-up. There was not a significant benefit of the injections when IKDC and WOMAC scores were evaluated. Hylan G-F 20 may be more beneficial for those patients who desire to increase their activity level rather than those who wish to decrease their pain. Level of Evidence: Level IV, therapeutic case series. |
| doi_str_mv | 10.1016/j.arthro.2007.10.014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70447693</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S074980630701081X</els_id><sourcerecordid>70447693</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-2441fc5c20ce0b4ad173ef4381b3de349cac3c0e6d6792da13a29fccf8d027543</originalsourceid><addsrcrecordid>eNqFkltrFDEUgIModlv9ByJ50bdZTy4zmXkRlmJbsdCCLfoWspkzbtbZyTbJFPbfN9NZFHzxKeHwndvHIeQdgyUDVn3aLk1Im-CXHEDl0BKYfEEWrORVIbhgL8kClGyKGipxQk5j3AKAELV4TU5YLVTJlViQX3cbpPcRqe_o1aE3A70sLigHuuoSBvptQKSr5z7R-v2BuoFmZmWTe0R6a5LDIdFbvx_7_PcD_eHSZs66iQn984guufiGvOpMH_Ht8T0j9xdf7s6viuuby6_nq-vCSgWp4FKyzpaWg0VYS9MyJbCTomZr0aKQjTVWWMCqrVTDW8OE4U1nbVe3wFUpxRn5ONfdB_8wYkx656LFPm-GfoxagZSqakQG5QzavFoM2Ol9cDsTDpqBngTrrZ4F60nwFM2Cc9r7Y_1xvcP2b9LRaAY-HAETrem7YAbr4h-OAy9lLp-5zzOH2cajw6CjzTItti6gTbr17n-T_FvA9m5wuedvPGDc-jEM2bRmOnIN-vt0DNMtgAIGNfspngAseq9S</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70447693</pqid></control><display><type>article</type><title>The Use of Hylan G-F 20 After Knee Arthroscopy in an Active Patient Population With Knee Osteoarthritis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Zietz, Patrick M., M.D ; Selesnick, Harlan, M.D</creator><creatorcontrib>Zietz, Patrick M., M.D ; Selesnick, Harlan, M.D</creatorcontrib><description>Purpose: The purpose of this study was to evaluate the efficacy of hylan G-F 20 when used to treat an active and athletic patient population with knee osteoarthritis who had undergone knee arthroscopy for mechanical symptoms. Methods: We performed a prospective evaluation of patients who underwent knee arthroscopy for mechanical symptoms. All patients had Outerbridge grade III or IV changes to their articular cartilage. If patients complained of residual pain or activity limitations postoperatively that was believed to be from osteoarthritis, they were treated with a series of hylan G-F 20 consisting of 3 weekly injections. International Knee Documentation Committee (IKDC) and Western Ontario and McMaster University Osteoarthritis Index (WOMAC) scores are reported for the time immediately before arthroscopy, at the time of the first hylan G-F 20 injection (baseline), at 3 months postoperatively, and at 6 months postoperatively. In addition, activity scores were calculated from a subset of the IKDC questionnaire before arthroscopy, at baseline, and at 3 months postoperatively. Results: Fifteen patients completed 6 months’ follow-up. Baseline and 3- and 6-month IKDC and WOMAC scores were significantly improved compared with before arthroscopy. There was no significant difference in 3- and 6-month scores compared with baseline. The activity scores at baseline and at 3 months showed significant improvement compared with before arthroscopy. The activity scores also showed significant improvement at 3 months compared with baseline. Conclusions: Hylan G-F 20 injections allow for improved activity levels at 3 months’ follow-up. There was not a significant benefit of the injections when IKDC and WOMAC scores were evaluated. Hylan G-F 20 may be more beneficial for those patients who desire to increase their activity level rather than those who wish to decrease their pain. Level of Evidence: Level IV, therapeutic case series.</description><identifier>ISSN: 0749-8063</identifier><identifier>EISSN: 1526-3231</identifier><identifier>DOI: 10.1016/j.arthro.2007.10.014</identifier><identifier>PMID: 18375273</identifier><identifier>CODEN: ARTHE3</identifier><language>eng</language><publisher>Philadelphia, PA: Elsevier Inc</publisher><subject>Arthroscopy ; Arthroscopy - adverse effects ; Arthroscopy - methods ; Athletic Injuries - diagnosis ; Athletic Injuries - therapy ; Biocompatible Materials ; Biological and medical sciences ; Combined Modality Therapy ; Diseases of the osteoarticular system ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Endoscopy ; Evaluation Studies as Topic ; Female ; Follow-Up Studies ; Humans ; Hyaluronic Acid - analogs & derivatives ; Hyaluronic Acid - therapeutic use ; Hylan G-F 20 ; Injections, Intra-Articular ; Investigative techniques, diagnostic techniques (general aspects) ; Male ; Medical sciences ; Orthopedic surgery ; Orthopedics ; Osteoarthritis ; Osteoarthritis, Knee - diagnosis ; Osteoarthritis, Knee - therapy ; Pain Measurement ; Pain, Postoperative - drug therapy ; Postoperative Care - methods ; Prospective Studies ; Range of Motion, Articular - drug effects ; Range of Motion, Articular - physiology ; Severity of Illness Index ; Sports ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Time Factors ; Treatment Outcome ; Viscosupplementation</subject><ispartof>Arthroscopy, 2008-04, Vol.24 (4), p.416-422</ispartof><rights>Arthroscopy Association of North America</rights><rights>2008 Arthroscopy Association of North America</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-2441fc5c20ce0b4ad173ef4381b3de349cac3c0e6d6792da13a29fccf8d027543</citedby><cites>FETCH-LOGICAL-c470t-2441fc5c20ce0b4ad173ef4381b3de349cac3c0e6d6792da13a29fccf8d027543</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S074980630701081X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20254101$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18375273$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zietz, Patrick M., M.D</creatorcontrib><creatorcontrib>Selesnick, Harlan, M.D</creatorcontrib><title>The Use of Hylan G-F 20 After Knee Arthroscopy in an Active Patient Population With Knee Osteoarthritis</title><title>Arthroscopy</title><addtitle>Arthroscopy</addtitle><description>Purpose: The purpose of this study was to evaluate the efficacy of hylan G-F 20 when used to treat an active and athletic patient population with knee osteoarthritis who had undergone knee arthroscopy for mechanical symptoms. Methods: We performed a prospective evaluation of patients who underwent knee arthroscopy for mechanical symptoms. All patients had Outerbridge grade III or IV changes to their articular cartilage. If patients complained of residual pain or activity limitations postoperatively that was believed to be from osteoarthritis, they were treated with a series of hylan G-F 20 consisting of 3 weekly injections. International Knee Documentation Committee (IKDC) and Western Ontario and McMaster University Osteoarthritis Index (WOMAC) scores are reported for the time immediately before arthroscopy, at the time of the first hylan G-F 20 injection (baseline), at 3 months postoperatively, and at 6 months postoperatively. In addition, activity scores were calculated from a subset of the IKDC questionnaire before arthroscopy, at baseline, and at 3 months postoperatively. Results: Fifteen patients completed 6 months’ follow-up. Baseline and 3- and 6-month IKDC and WOMAC scores were significantly improved compared with before arthroscopy. There was no significant difference in 3- and 6-month scores compared with baseline. The activity scores at baseline and at 3 months showed significant improvement compared with before arthroscopy. The activity scores also showed significant improvement at 3 months compared with baseline. Conclusions: Hylan G-F 20 injections allow for improved activity levels at 3 months’ follow-up. There was not a significant benefit of the injections when IKDC and WOMAC scores were evaluated. Hylan G-F 20 may be more beneficial for those patients who desire to increase their activity level rather than those who wish to decrease their pain. Level of Evidence: Level IV, therapeutic case series.</description><subject>Arthroscopy</subject><subject>Arthroscopy - adverse effects</subject><subject>Arthroscopy - methods</subject><subject>Athletic Injuries - diagnosis</subject><subject>Athletic Injuries - therapy</subject><subject>Biocompatible Materials</subject><subject>Biological and medical sciences</subject><subject>Combined Modality Therapy</subject><subject>Diseases of the osteoarticular system</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Endoscopy</subject><subject>Evaluation Studies as Topic</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Hyaluronic Acid - analogs & derivatives</subject><subject>Hyaluronic Acid - therapeutic use</subject><subject>Hylan G-F 20</subject><subject>Injections, Intra-Articular</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Orthopedic surgery</subject><subject>Orthopedics</subject><subject>Osteoarthritis</subject><subject>Osteoarthritis, Knee - diagnosis</subject><subject>Osteoarthritis, Knee - therapy</subject><subject>Pain Measurement</subject><subject>Pain, Postoperative - drug therapy</subject><subject>Postoperative Care - methods</subject><subject>Prospective Studies</subject><subject>Range of Motion, Articular - drug effects</subject><subject>Range of Motion, Articular - physiology</subject><subject>Severity of Illness Index</subject><subject>Sports</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Viscosupplementation</subject><issn>0749-8063</issn><issn>1526-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkltrFDEUgIModlv9ByJ50bdZTy4zmXkRlmJbsdCCLfoWspkzbtbZyTbJFPbfN9NZFHzxKeHwndvHIeQdgyUDVn3aLk1Im-CXHEDl0BKYfEEWrORVIbhgL8kClGyKGipxQk5j3AKAELV4TU5YLVTJlViQX3cbpPcRqe_o1aE3A70sLigHuuoSBvptQKSr5z7R-v2BuoFmZmWTe0R6a5LDIdFbvx_7_PcD_eHSZs66iQn984guufiGvOpMH_Ht8T0j9xdf7s6viuuby6_nq-vCSgWp4FKyzpaWg0VYS9MyJbCTomZr0aKQjTVWWMCqrVTDW8OE4U1nbVe3wFUpxRn5ONfdB_8wYkx656LFPm-GfoxagZSqakQG5QzavFoM2Ol9cDsTDpqBngTrrZ4F60nwFM2Cc9r7Y_1xvcP2b9LRaAY-HAETrem7YAbr4h-OAy9lLp-5zzOH2cajw6CjzTItti6gTbr17n-T_FvA9m5wuedvPGDc-jEM2bRmOnIN-vt0DNMtgAIGNfspngAseq9S</recordid><startdate>20080401</startdate><enddate>20080401</enddate><creator>Zietz, Patrick M., M.D</creator><creator>Selesnick, Harlan, M.D</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20080401</creationdate><title>The Use of Hylan G-F 20 After Knee Arthroscopy in an Active Patient Population With Knee Osteoarthritis</title><author>Zietz, Patrick M., M.D ; Selesnick, Harlan, M.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-2441fc5c20ce0b4ad173ef4381b3de349cac3c0e6d6792da13a29fccf8d027543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Arthroscopy</topic><topic>Arthroscopy - adverse effects</topic><topic>Arthroscopy - methods</topic><topic>Athletic Injuries - diagnosis</topic><topic>Athletic Injuries - therapy</topic><topic>Biocompatible Materials</topic><topic>Biological and medical sciences</topic><topic>Combined Modality Therapy</topic><topic>Diseases of the osteoarticular system</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Endoscopy</topic><topic>Evaluation Studies as Topic</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Hyaluronic Acid - analogs & derivatives</topic><topic>Hyaluronic Acid - therapeutic use</topic><topic>Hylan G-F 20</topic><topic>Injections, Intra-Articular</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Orthopedic surgery</topic><topic>Orthopedics</topic><topic>Osteoarthritis</topic><topic>Osteoarthritis, Knee - diagnosis</topic><topic>Osteoarthritis, Knee - therapy</topic><topic>Pain Measurement</topic><topic>Pain, Postoperative - drug therapy</topic><topic>Postoperative Care - methods</topic><topic>Prospective Studies</topic><topic>Range of Motion, Articular - drug effects</topic><topic>Range of Motion, Articular - physiology</topic><topic>Severity of Illness Index</topic><topic>Sports</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Viscosupplementation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zietz, Patrick M., M.D</creatorcontrib><creatorcontrib>Selesnick, Harlan, M.D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Arthroscopy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zietz, Patrick M., M.D</au><au>Selesnick, Harlan, M.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Use of Hylan G-F 20 After Knee Arthroscopy in an Active Patient Population With Knee Osteoarthritis</atitle><jtitle>Arthroscopy</jtitle><addtitle>Arthroscopy</addtitle><date>2008-04-01</date><risdate>2008</risdate><volume>24</volume><issue>4</issue><spage>416</spage><epage>422</epage><pages>416-422</pages><issn>0749-8063</issn><eissn>1526-3231</eissn><coden>ARTHE3</coden><abstract>Purpose: The purpose of this study was to evaluate the efficacy of hylan G-F 20 when used to treat an active and athletic patient population with knee osteoarthritis who had undergone knee arthroscopy for mechanical symptoms. Methods: We performed a prospective evaluation of patients who underwent knee arthroscopy for mechanical symptoms. All patients had Outerbridge grade III or IV changes to their articular cartilage. If patients complained of residual pain or activity limitations postoperatively that was believed to be from osteoarthritis, they were treated with a series of hylan G-F 20 consisting of 3 weekly injections. International Knee Documentation Committee (IKDC) and Western Ontario and McMaster University Osteoarthritis Index (WOMAC) scores are reported for the time immediately before arthroscopy, at the time of the first hylan G-F 20 injection (baseline), at 3 months postoperatively, and at 6 months postoperatively. In addition, activity scores were calculated from a subset of the IKDC questionnaire before arthroscopy, at baseline, and at 3 months postoperatively. Results: Fifteen patients completed 6 months’ follow-up. Baseline and 3- and 6-month IKDC and WOMAC scores were significantly improved compared with before arthroscopy. There was no significant difference in 3- and 6-month scores compared with baseline. The activity scores at baseline and at 3 months showed significant improvement compared with before arthroscopy. The activity scores also showed significant improvement at 3 months compared with baseline. Conclusions: Hylan G-F 20 injections allow for improved activity levels at 3 months’ follow-up. There was not a significant benefit of the injections when IKDC and WOMAC scores were evaluated. Hylan G-F 20 may be more beneficial for those patients who desire to increase their activity level rather than those who wish to decrease their pain. Level of Evidence: Level IV, therapeutic case series.</abstract><cop>Philadelphia, PA</cop><pub>Elsevier Inc</pub><pmid>18375273</pmid><doi>10.1016/j.arthro.2007.10.014</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0749-8063 |
| ispartof | Arthroscopy, 2008-04, Vol.24 (4), p.416-422 |
| issn | 0749-8063 1526-3231 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70447693 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Arthroscopy Arthroscopy - adverse effects Arthroscopy - methods Athletic Injuries - diagnosis Athletic Injuries - therapy Biocompatible Materials Biological and medical sciences Combined Modality Therapy Diseases of the osteoarticular system Dose-Response Relationship, Drug Drug Administration Schedule Endoscopy Evaluation Studies as Topic Female Follow-Up Studies Humans Hyaluronic Acid - analogs & derivatives Hyaluronic Acid - therapeutic use Hylan G-F 20 Injections, Intra-Articular Investigative techniques, diagnostic techniques (general aspects) Male Medical sciences Orthopedic surgery Orthopedics Osteoarthritis Osteoarthritis, Knee - diagnosis Osteoarthritis, Knee - therapy Pain Measurement Pain, Postoperative - drug therapy Postoperative Care - methods Prospective Studies Range of Motion, Articular - drug effects Range of Motion, Articular - physiology Severity of Illness Index Sports Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Time Factors Treatment Outcome Viscosupplementation |
| title | The Use of Hylan G-F 20 After Knee Arthroscopy in an Active Patient Population With Knee Osteoarthritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T17%3A27%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Use%20of%20Hylan%20G-F%2020%20After%20Knee%20Arthroscopy%20in%20an%20Active%20Patient%20Population%20With%20Knee%20Osteoarthritis&rft.jtitle=Arthroscopy&rft.au=Zietz,%20Patrick%20M.,%20M.D&rft.date=2008-04-01&rft.volume=24&rft.issue=4&rft.spage=416&rft.epage=422&rft.pages=416-422&rft.issn=0749-8063&rft.eissn=1526-3231&rft.coden=ARTHE3&rft_id=info:doi/10.1016/j.arthro.2007.10.014&rft_dat=%3Cproquest_cross%3E70447693%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70447693&rft_id=info:pmid/18375273&rft_els_id=S074980630701081X&rfr_iscdi=true |